Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Profile of M21 human melanoma cells analyzed by flow cytometry using clone 9.2.27 (Cat. No. 554275). Cells were incubated with either Purified Mouse anti-Chondroitin Sulfate or Purified Mouse IgG2a, κ Isotype Control, and detected with a FITC conjugated second step antibody (Cat. No.555988).
Profile of M21 human melanoma cells analyzed by flow cytometry using clone 9.2.27 (Cat. No. 554275). Cells were incubated with either Purified Mouse anti-Chondroitin Sulfate or Purified Mouse IgG2a, κ Isotype Control, and detected with a FITC conjugated second step antibody (Cat. No.555988).
Profile of M21 human melanoma cells analyzed by flow cytometry using clone 9.2.27 (Cat. No. 554275). Cells were incubated with either Purified Mouse anti-Chondroitin Sulfate or Purified Mouse IgG2a, κ Isotype Control, and detected with a FITC conjugated second step antibody (Cat. No.555988).
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Clone 9.2.27 specifically reacts with a chondroitin sulfate proteoglycan. By immunoprecipitation, it recognizes the fully processed 250 kDa core glycoprotein and a set of precursor polypeptides (210 kDa, 220 kDa, and 240 kDa).
Applications include immunoprecipitation (1 µg/1x10^6 cells), flow cytometry (1-2 µg/ 1x10^6 cells) and immunoflourescence microscopy of cultured cells.
The 9.2.27 monoclonal antibody specifically binds to CSPG4 (chondroitin sulfate proteoglycan 4). CSPG4 is also known as MCSP (melanoma chondroitin sulfate proteoglycan) and NG2 (neural/glial antigen 2). The hybridoma secreting the 9.2.27 antibody was generated using a human melanoma cell extract as the immunogen. Tumor cells display a variety of antigens which have been defined by antibodies. Antibodies that specifically react with tumor-associated antigens are useful in understanding the biology of particular tumor types. Proteoglycans including chondroitin sulfate, keratan sulfate, dermatan sulfate and heparan sulfate are major components of the extracellular matrices of many animal cell types. Clone 9.2.27 has been shown to react with human melanoma cells, glioma cells, and proliferating brain endothelial cells. It did not react with fetal melanocytes, neuroblastoma LA-N-1 cells or a variety of carcinoma, lymphoid, and fibroblastoid cell lines. Additionally, neither white nor gray matter from the medulla oblongata, cerebellum or spinal cord of a normal human adult reacted with 9.2.27. Clone 9.2.27 has also been used in functional studies to investigate the role of chondroitin sulfate proteoglycans in human tumor cell systems. It has been shown to block melanoma cell spreading, exhibit antiproliferative effects on glioma cells in vitro and suppress glioma tumor growth in athymic nude mice models.
A soluble extract derived from M14 human melanoma cells bound to lens culinaris lectin-Sepharose and depleted of fibronectin was used as immunogen.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.